New drug cocktail targets breast cancer brain metastases
NCT ID NCT03417544
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs (atezolizumab, pertuzumab, and high-dose trastuzumab) in 19 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors. While the approach aims to manage the disease, ongoing treatment is typically needed, so this is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could immune activators revive treatment for Hard-to-Treat breast cancer?
- DNA vaccine aims to train immune system against breast cancer
- New drug challenger takes on leading therapy for advanced breast cancer
- Spinal fluid may hold clues to breast cancer brain spread
- New cocktail of drugs aims to keep HER2+ breast cancer in check
- Kazakhstan cancer study to reveal Real-World treatment patterns